Alzheimer's disease amyloid-beta peptide modulates apolipoprotein E isoform specific receptor binding

Journal of Alzheimer's Disease

Volumn 7, Issue 4, 2005, Pages 303-314

  Hone, E ^a,b   Martins, I J ^a   Jeoung, M ^d   Ji, T H ^d   Gandy, S E ^a,c   Martins, R N ^a,b  

^a EDITH COWAN UNIVERSITY   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Alzheimer's disease; Amyloid ; Apolipoprotein E; Cholesterol; Lipoproteins; Periphery

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; CHOLESTEROL; ISOPROTEIN;

ALZHEIMER DISEASE; ARTICLE; CELL LABELING; CHOLESTEROL METABOLISM; CONTROLLED STUDY; FIBROBLAST CULTURE; FLUORESCENCE ANALYSIS; HUMAN; HUMAN CELL; MEDICAL ASSESSMENT; MICROEMULSION; NEUROMODULATION; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; PROTEIN VARIANT; RECEPTOR OCCUPANCY;

EID: 23944511140     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2005-7406     Document Type: Article

References (78)

1. S. Aleshkov, C.R. Abraham and V.I. Zannis, Interaction of nascent ApoE2, ApoE3, and ApoE4 isoforms expressed in mammalian cells with amyloid peptide beta (1-40). Relevance to Alzheimer's disease, Biochemistry 36 (1997), 10571-10580.
2. S.B. Aleshkov, X. Li, S.N. Lavrentiadou and V.I. Zannis, Contribution of cysteine 158, the glycosylation site threonine 194, the amino- and carboxy-terminal domains of apolipoprotein E in the binding to amyloid peptide beta (1-40), Biochemistry 38 (1999), 8918-8925.
3. K.R. Bales, T. Verina, R.C. Dodel, Y. Du, L. Altstiel, M. Bender, P. Hyslop, E.M. Johnstone, S.P. Little, D.J. Cummins, P. Piccardo, B. Ghetti and S.M. Paul, Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition [letter], Nature Genetics 17 (1997), 263-264.
4. U. Beffert, N. Aumont, D. Dea, S. Lussier-Cacan, J. Davignon and J. Poirier, Beta-amyloid peptides increase the binding and internalization of apolipoprotein E to hippocampal neurons, Journal of Neurochemistry 70 (1998), 1458-1466.
5. I. Bjorkhem and S. Meaney, Brain Cholesterol: Long Secret Life Behind a Barrier, Arterioscler Thromb Vasc Biol 5 (2004), 5.
6. R. Brasseur, T. Pillot, L. Lins, J. Vandekerckhove and M. Rosseneu, Peptides in membranes: tipping the balance of membrane stability, Trends in Biochemical Sciences 22 (1997), 167-171.
7. M.S. Brown and J.L. Goldstein, A receptor-mediated pathway for cholesterol homeostasis, Science 232 (1986), 34-47.
8. M.S. Brown, P.T. Kovanen and J.L. Goldstein, Regulation of plasma cholesterol by lipoprotein receptors, Science 212 (1981), 628-635.
9. L. Buee, W. Ding, J.P. Anderson, S. Narindrasorasak, R. Kisilevsky, N.J. Boyle, N.K. Robakis, A. Delacourte, B. Greenberg and H.M. Fillit, Binding of vascular heparan sulfate proteoglycan to Alzheimer's amyloid precursor protein is mediated in part by the N-terminal region of A4 peptide, Brain Research 627 (1993), 199-204.
10. D.A. Butterfield, beta-Amyloid-associated free radical oxidative stress and neurotoxicity: implications for Alzheimer's disease, Chemical Research in Toxicology 10 (1997), 495-506.
11. S.Y. Choi, L.G. Fong, M.J. Kirven and A.D. Cooper, Use of an anti-low density lipoprotein receptor antibody to quantify the role of the LDL receptor in the removal of chylomicron remnants in the mouse in vivo, Journal of Clinical Investigation 88 (1991), 1173-1181.
12. E.H. Corder, A.M. Saunders, W.J. Strittmatter, D.E. Schmechel, P.C. Gaskell, G.W. Small, A.D. Roses, J.L. Haines and M.A. Pericak-Vance, Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families, Science 261 (1993), 921-923.
13. L.M. Dong, S. Parkin, S.D. Trakhanov, B. Rupp, T. Simmons, K.S. Arnold, Y.M. Newhouse, T.L. Innerarity and K.H. Weisgraber, Novel mechanism for defective receptor binding of apolipoprotein E2 in type III hyperlipoproteinemia, Nature Structural Biology 3 (1996), 718-722.
14. J.E. Eichner, L.H. Kuller, T.J. Orchard, G.A. Grandits, L.M. McCallum, R.E. Ferrell and J.D. Neaton, Relation of apolipoprotein E phenotype to myocardial infarction and mortality from coronary artery disease, American Journal of Cardiology 71 (1993), 160-165.
15. V. Esser, L.E. Limbird, M.S. Brown, J.L. Goldstein and D.W. Russell, Mutational analysis of the ligand binding domain of the low density lipoprotein receptor, Journal of Biological Chemistry 263 (1988), 13282-13290.
16. R.M. Evans, C.L. Emsley, S. Gao, A. Sahota, K.S. Hall, M.R. Farlow and H. Hendrie, Serum cholesterol, APOE genotype, and the risk of Alzheimer's disease: a population-based study of African Americans, Neurology 54 (2000), 240-242.
17. K. Fassbender, M. Simons, C. Bergmann, M. Stroick, D. Lutjohann, P. Keller, H. Runz, S. Kuhl, T. Bertsch, K. von Bergmann, M. Hennerici, K. Beyreuther and T. Hartmann, Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo, Proc Natl Acad Sci USA 98 (2001), 5856-5861.
18. J. Fonte, J. Miklossy, C. Atwood and R. Martins, The severity of cortical Alzheimer's type changes is positively correlated with increased amyloid-beta Levels: Resolubilization of amyloid-beta with transition metal ion chelators, J Alzheimers Dis 3 (2001), 209-219.
19. J.D. Fryer, J.W. Taylor, R.B. DeMattos, K.R. Bales, S.M. Paul, M. Parsadanian and D.M. Holtzman, Apolipoprotein E markedly facilitates age-dependent cerebral amyloid angiopathy and spontaneous hemorrhage in amyloid precursor protein transgenic mice, J Neurosci 23 (2003), 7889-7896.
20. Y. Fujioka, A.D. Cooper and L.G. Fong, Multiple processes are involved in the uptake of chylomicron remnants by mouse peritoneal macrophages, Journal of Lipid Research 39 (1998), 2339-2349.
21. S.M. Hammad, S. Ranganathan, E. Loukinova, W.O. Twal and W.S. Argraves, Interaction of apolipoprotein J-amyloid beta-peptide complex with low density lipoprotein receptor-related protein-2/megalin. A mechanism to prevent pathological accumulation of amyloid beta-peptide, Journal of Biological Chemistry 272 (1997), 18644-18649.
22. E. Hollenbach, S. Ackermann, B.T. Hyman and G.W. Rebeck, Confirmation of an association between a polymorphism in exon 3 of the low-density lipoprotein receptor-related protein gene and Alzheimer's disease, Neurology 50 (1998), 1905-1907.
23. D.M. Holtzman, R.E. Pitas, J. Kilbridge, B. Nathan, R.W. Mahley, G. Bu and A.L. Schwartz, Low density lipoprotein receptor-related protein mediates apolipoprotein E-dependent neurite outgrowth in a central nervous system-derived neuronal cell line, Proceedings of the National Academy of Sciences of the United States of Americe 92 (1995), 9480-9484.
24. E. Hone, I.J. Martins, J. Fonte and R.N. Martins, Apolipoprotein E influences amyloid-beta clearance from the murine periphery, J Alzheimers Dis 5 (2003), 1-8.
25. B.T. Hyman, T. Gomez-Isla, G.W. Rebeck, M. Briggs, H. Chung, H.L. West, S. Greenberg, S. Mui, S. Nichols, R. Wallace and J.H. Growdon, Epidemiological, clinical, and neuropathological study of apolipoprotein E genotype in Alzheimer's disease, Annals of the New York Academy of Sciences 802 (1996), 1-5.
26. T. Isaka, T. Yoshimine, M. Maruno, R. Kuroda, H. Ishii, T. Hayakawa, E.D. Litwack, C.S. Stipp, A. Kumbasar and A.D. Lander, Altered expression of antithrombotic molecules in human glioma vessels Neuronal expression of glypican, a cell-surface glycosylphosphatidylinositol-anchored heparan sulfate proteoglycan, in the adult rat nervous system, Acta Neuropathologica 87 (1994), 81-85.
27. T.H. Ji, The application of chemical crosslinking for studies on cell membranes and the identification of surface reporters, Biochim Biophys Acta 559 (1979), 39-69.
28. Z.S. Ji, W.J. Brecht, R.D. Miranda, M.M. Hussain, T.L. Innerarity and R.W. Mahley, Role of heparan sulfate proteoglycans in the binding and uptake of apolipoprotein E-enriched remnant lipoproteins by cultured cells, Journal of Biological Chemistry 268 (1993), 10160-10167.
29. Z.S. Ji, S. Fazio, Y.L. Lee and R.W. Mahley, Secretion-capture role for apolipoprotein E in remnant lipoprotein metabolism involving cell surface heparan sulfate proteoglycans, Journal of Biological Chemistry 269 (1994), 2764-2772.
30. Z.S. Ji, D.A. Sanan and R.W. Mahley, Intravenous heparinase inhibits remnant lipoprotein clearance from the plasma and uptake by the liver: in vivo role of heparan sulfate proteoglycans, Journal of Lipid Research 36 (1995), 583-592.
31. H. Jick, G.L. Zornberg, S.S. Jick, S. Seshadri and D.A. Drachman, Statins and the risk of dementia, Lancet 356 (2000), 1627-1631.
32. M.I. Kamboh, R.E. Ferrell and S.T. DeKosky, Genetic association studies between Alzheimer's disease and two polymorphisms in the low density lipoprotein receptor-related protein gene, Neuroscience Letters 244 (1998), 65-68.
33. D.E. Kang, C.U. Pietrzik, L. Baum, N. Chevallier, D.E. Merriam, M.Z. Kounnas, S.L. Wagner, J.C. Troncoso, C.H. Kawas, R. Katzman and E.H. Koo, Modulation of amyloid beta-protein clearance and Alzheimer's disease susceptibility by the LDL receptor-related protein pathway, Journal of Clinical Investigation 106 (2000), 1159-1166.
34. D.E. Kang, T. Saitoh, X. Chen, Y. Xia, E. Masliah, L.A. Hansen, R.G. Thomas, L.J. Thal and R. Katzman, Genetic association of the low-density lipoprotein receptor-related protein gene (LRP), an apolipoprotein E receptor, with late-onset Alzheimer's disease, Neurology 49 (1997), 56-61.
35. E. Kojro, G. Gimpl, S. Lammich, W. Marz and F. Fahrenholz, Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha -secretase ADAM 10, Proc Natl Acad Sci USA 98 (2001), 5815-5820.
36. M.J. LaDu, M.T. Falduto, A.M. Manelli, C.A. Reardon, G.S. Getz and D.E. Frail, Isoform-specific binding of apolipoprotein E to beta-amyloid, Journal of Biological Chemistry 269 (1994), 23403-23406.
37. M.J. LaDu, J.R. Lukens, C.A. Reardon and G.S. Getz, Association of human, rat, and rabbit apolipoprotein E with beta-amyloid, Journal of Neuroscience Research 49 (1997), 9-18.
38. M.J. LaDu, T.M. Pederson, D.E. Frail, C.A. Reardon, G.S. Getz and M.T. Falduto, Purification of apolipoprotein E attenuates isoform-specific binding to beta-amyloid, Journal of Biological Chemistry 270 (1995), 9039-9042.
39. J.C. Lambert, F. Wavrant-De Vrieze, P. Amouyel and M.C. Chartier-Harlin, Association at LRP gene locus with sporadic late-onset Alzheimer's disease [letter], Lancet 351 (1998), 1787-1788.
40. S.M. Laws, E. Hone, S. Gandy and R.N. Martins, Expanding the association between the APOE gene and the risk of Alzheimer's disease: possible roles for APOE promoter polymorphisms and alterations in APOE transcription, J Neurochem 84 (2003), 1215-1236.
41. E.D. Litwack, C.S. Stipp, A. Kumbasar and A.D. Lander, Neuronal expression of glypican, a cell-surface glycosylphosphatidylinositol-anchored heparan sulfate proteoglycan, in the adult rat nervous system, Journal of Neuroscience 14 (1994), 3713-3724.
42. H.C. Liu, C.J. Hong, S.J. Wang, J.L. Fuh, P.N. Wang, H.Y. Shyu and E.L. Teng, ApoE genotype in relation to AD and cholesterol: a study of 2,326 Chinese adults, Neurology 53 (1999), 962-966.
43. R.W. Mahley, The molecular basis of atherosclerosis: concepts derived from studies of lipoprotein metabolism and cell biology, Clinical & Investigative Medicine - Medecine Clinique et Experimentale 9 (1986), 304-308.
44. R.W. Mahley, Apolipoprotein E: cholesterol transport protein with expanding role in cell biology, Science 240 (1988), 622-630.
45. R.W. Mahley, Heparan sulfate proteoglycan/low density lipoprotein receptor-related protein pathway involved in type III hyperlipoproteinemia and Alzheimer's disease, Israel Journal of Medical Sciences 32 (1996), 414-429.
46. R.W. Mahley and Z.S. Ji, Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E, Journal of Lipid Research 40 (1999), 1-16.
47. R.W. Mahley, Z.S. Ji, W.J. Brecht, R.D. Miranda and D. He, Role of heparan sulfate proteoglycans and the LDL receptor-related protein in remnant lipoprotein metabolism, Annals of the New York Academy of Sciences 737 (1994), 39-52.
48. I.J. Martins, E. Hone, C. Chi, U. Seydel, R.N. Martins and T.G. Redgrave, Relative roles of LDLr and LRP in the metabolism of chylomicron remnants in genetically manipulated mice, Journal of Lipid Research 41 (2000), 205-213.
49. I.J. Martins, B.C. Mortimer, J. Miller and T.G. Redgrave, Effects of particle size and number on the plasma clearance of chylomicrons and remnants, Journal of Lipid Research 37 (1996), 2696-2705.
50. I.J. Martins and T.G. Redgrave, A 13CO2 breath test to assess the metabolism of triglyceride-rich lipoprotein remnants in mice, Journal of Lipid Research 39 (1998), 691-698.
51. I.J. Martins, C. Vilcheze, B.C. Mortimer, R. Bittman and T.G. Redgrave, Sterol side chain length and structure affect the clearance of chylomicron-like lipid emulsions in rats and mice, Journal of Lipid Research 39 (1998), 302-312.
52. M. Michikawa, The role of cholesterol in pathogenesis of Alzheimer's disease: dual metabolic interaction between amyloid beta-protein and cholesterol, Mol Neurobiol 27 (2003), 1-12.
53. T. Ou, K. Yamakawa-Kobayashi, T. Arinami, H. Amemiya, H. Fujiwara, K. Kawata, M. Saito, S. Kikuchi, Y. Noguchi, Y. Sugishita and H. Hamaguchi, Methylenetetrahydrofolate reductase and apolipoprotein E polymorphisms are independent risk factors for coronary heart disease in Japanese: a case-control study, Atherosclerosis 137 (1998), 23-28.
54. T. Pillot, M. Goethals, J. Najib, C. Labeur, L. Lins, J. Chambaz, R. Brasseur, J. Vandekerckhove and M. Rosseneu, Beta-amyloid peptide interacts specifically with the carboxy-terminal domain of human apolipoprotein E: relevance to Alzheimer's disease, Journal of Neurochemistry 72 (1999), 230-237.
55. L. Puglielli, R.E. Tanzi and D.M. Kovacs, Alzheimer's disease: the cholesterol connection, Nat Neurosci 6 (2003), 345-351.
56. S.C. Rall, Jr., K.H. Weisgraber, T.L. Innerarity and R.W. Mahley, Structural basis for receptor binding heterogeneity of apolipoprotein E from type III hyperlipoproteinemic subjects, Proceedings of the National Academy of Sciences of the United States of America 79 (1982), 4696-4700.
57. G.W. Rebeck, J.S. Reiter, D.K. Strickland and B.T. Hyman, Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions, Neuron 11 (1993), 575-580.
58. T.G. Redgrave, C.L. Elsegood, J.C. Mamo and M.J. Callow, Effects of hypothyroidism on the metabolism of lipid emulsion models of triacylglycerol-rich lipoproteins in rats, Biochemical Journal 273 (1991), 375-381.
59. A.M. Saunders, W.J. Strittmatter, D. Schmechel, P.H. George-Hyslop, M.A. Pericak-Vance, S.H. Joo, B.L. Rosi, J.F. Gusella, D.R. Crapper-MacLachlan, M.J. Alberts et al., Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease, Neurology 43 (1993), 1467-1472.
60. W.J. Schneider, P.T. Kovanen, M.S. Brown, J.L. Goldstein, G. Utermann, W. Weber, R.J. Havel, L. Kotite, J.P. Kane, T.L. Innerarity and R.W. Mahley, Familial dysbetalipoproteinemia. Abnormal binding of mutant apoprotein E to low density lipoprotein receptors of human fibroblasts and membranes from liver and adrenal of rats, rabbits, and cows, Journal of Clinical Investigation 68 (1981), 1075-1085.
61. M. Shibata, S. Yamada, S.R. Kumar, M. Calero, J. Bading, B. Frangione, D.M. Holtzman, C.A. Miller, D.K. Strickland, J. Ghiso and B.V. Zlokovic, Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier, Journal of Clinical Investigation 106 (2000), 1489-1499.
62. D.L. Sparks, Intraneuronal beta-amyloid immunoreactivity in the CNS, Neurobiology of Aging 17 (1996), 291-299.
63. D.L. Sparks, T.A. Martin, D.R. Gross and J.C. Hunsaker, 3rd., Link between heart disease, cholesterol, and Alzheimer's disease: a review, Microscopy Research & Technique 50 (2000), 287-290.
64. J.T. Sparrow, D.A. Sparrow, G. Fernando, A.R. Culwell, M. Kovar and A.M. Gotto, Jr., Apolipoprotein E: phospholipid binding studies with synthetic peptides from the carboxyl terminus, Biochemistry 31 (1992), 1065-1068.
65. W.J. Strittmatter, A.M. Saunders, D. Schmechel, M. Pericak-Vance, J. Enghild, G.S. Salvesen and A.D. Roses, Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease, Proceedings of the National Academy of Sciences of the United States of America 90 (1993), 1977-1981.
66. W.J. Strittmatter, K.H. Weisgraber, D.Y. Huang, L.M. Dong, G.S. Salvesen, M. Pericak-Vance, D. Schmechel, A.M. Saunders, D. Goldgaber and A.D. Roses, Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease, Proceedings of the National Academy of Sciences of the United States of America 90 (1993), 8098-8102.
67. C. Talbot, C. Lendon, N. Craddock, S. Shears, J.C. Morris and A. Goate, Protection against Alzheimer's disease with apoE epsilon 2 [letter], Lancet 343 (1994), 1432-1433.
68. G. Utermann, Apolipoprotein E polymorphism in health and disease, American Heart Journal 113 (1987), 433-440.
69. F. Wavrant-DeVrieze, J.C. Lambert, L. Stas, R. Crook, D. Cottel, F. Pasquier, B. Frigard, M. Lambrechts, E. Thiry, P. Amouyel, J.P. Tur, M.C. Chartier-Harlin, J. Hardy and F. Van Leuven, Association between coding variability in the LRP gene and the risk of late-onset Alzheimer's disease, Human Genetics 104 (1999), 432-434.
70. H. Wehr, T. Parnowski, S. Puzynski, M. Bednarska-Makaruk, M. Bisko, S. Kotapka-Minc, M. Rodo and M. Wolkowska, Apolipoprotein E genotype and lipid and lipoprotein levels in dementia, Dementia & Geriatric Cognitive Disorders 11 (2000), 70-73.
71. T.E. Willnow, Mechanisms of hepatic chylomicron remnant clearance, Diabetic Medicine 14 (1997), S75-S80.
72. K. Winkler, H. Scharnagl, U. Tisljar, H. Hoschutzky, I. Friedrich, M.M. Hoffmann, M. Huttinger, H. Wieland and W. Marz, Competition of Abeta amyloid peptide and apolipoprotein E for receptor-mediated endocytosis, Journal of Lipid Research 40 (1999), 447-455.
73. B.B. Wolf, M.B. Lopes, S.R. VandenBerg and S.L. Gonias, Characterization and immunohistochemical localization of alpha 2-macroglobulin receptor (low-density lipoprotein receptor-related protein) in human brain, American Journal of Pathology 141 (1992), 37-42.
74. B. Wolozin, W. Kellman, P. Ruosseau, G.G. Celesia and G. Siegel, Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3- methyglutaryl coenzyme A reductase inhibitors, Archives of Neurology 57 (2000), 1439-1443.
75. W.G. Wood and U. Igbavboa, Cholesterol trafficking and amyloid beta peptides, Pharmacopsychiatry 36 (2003), S144-S148.
76. D.S. Yang, D.H. Small, U. Seydel, J.D. Smith, J. Hallmayer, S.E. Gandy and R.N. Martins, Apolipoprotein E promotes the binding and uptake of beta-amyloid into Chinese hamster ovary cells in an isoform-specific manner, Neuroscience 90 (1999), 1217-1226.
77. D.S. Yang, J.D. Smith, Z. Zhou, S.E. Gandy and R.N. Martins, Characterization of the binding of amyloid-beta peptide to cell culture-derived native apolipoprotein E2, E3, and E4 isoforms and to isoforms from human plasma, Journal of Neurochemistry 68 (1997), 721-725.
78. Z. Zhou, J.D. Smith, P. Greengard and S. Gandy, Alzheimer amyloid-beta peptide forms denaturant-resistant complex with type epsilon 3 but not type epsilon 4 isoform of native apolipoprotein E, Molecular Medicine 2 (1996), 175-180.